Seelos Historical Income Statement

SEEL Stock  USD 0.33  0.01  2.94%   
Historical analysis of Seelos Therapeutics income statement accounts such as Gross Profit of 2.3 M, Other Operating Expenses of 23.6 M, Research Development of 31.6 M or Total Operating Expenses of 22.6 M can show how well Seelos Therapeutics performed in making a profits. Evaluating Seelos Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Seelos Therapeutics's future profits or losses.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Seelos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Seelos Therapeutics is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.

About Seelos Income Statement Analysis

Seelos Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Seelos Therapeutics shareholders. The income statement also shows Seelos investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Seelos Therapeutics Income Statement Chart

Seelos Therapeutics Income Statement is one of the three primary financial statements used for reporting Seelos's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Seelos Therapeutics revenue and expense. Seelos Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Seelos Therapeutics' Net Interest Income is quite stable compared to the past year.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Seelos Therapeutics. It is also known as Seelos Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Seelos Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Seelos Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.At this time, Seelos Therapeutics' Net Interest Income is quite stable compared to the past year.
 2010 2023 2024 (projected)
Extraordinary Items691K621.9K552.8K
Non Recurring8.3M7.4M6.6M

Seelos Therapeutics income statement Correlations

0.29-0.110.21-0.05-0.580.60.6-0.610.62-0.590.53-0.190.170.53-0.010.550.010.05-0.03-0.03-0.370.130.33-0.03
0.290.470.20.30.3-0.2-0.210.14-0.20.27-0.150.17-0.3-0.130.21-0.10.320.310.250.25-0.650.050.040.25
-0.110.470.410.320.64-0.56-0.520.4-0.510.6-0.520.32-0.31-0.49-0.06-0.40.09-0.120.020.02-0.24-0.01-0.070.02
0.210.20.410.54-0.040.150.2-0.180.21-0.090.160.17-0.250.230.170.290.370.020.030.03-0.560.590.470.03
-0.050.30.320.540.17-0.12-0.10.11-0.10.140.070.07-0.940.080.560.070.630.09-0.16-0.16-0.490.520.11-0.16
-0.580.30.64-0.040.17-0.96-0.960.93-0.961.0-0.920.41-0.29-0.92-0.22-0.89-0.21-0.09-0.05-0.050.12-0.4-0.53-0.05
0.6-0.2-0.560.15-0.12-0.960.99-0.970.99-0.960.96-0.430.280.960.240.940.270.140.250.25-0.270.510.650.25
0.6-0.21-0.520.2-0.1-0.960.99-0.981.0-0.960.94-0.430.280.950.20.940.270.10.260.26-0.290.530.660.26
-0.610.140.4-0.180.110.93-0.97-0.98-0.980.94-0.920.42-0.27-0.93-0.2-0.93-0.29-0.07-0.29-0.290.32-0.52-0.67-0.29
0.62-0.2-0.510.21-0.1-0.960.991.0-0.98-0.960.94-0.430.280.950.20.940.270.10.250.25-0.290.520.660.25
-0.590.270.6-0.090.141.0-0.96-0.960.94-0.96-0.920.39-0.28-0.93-0.23-0.9-0.24-0.08-0.05-0.050.17-0.44-0.55-0.05
0.53-0.15-0.520.160.07-0.920.960.94-0.920.94-0.92-0.470.060.990.480.980.480.270.150.15-0.260.60.670.15
-0.190.170.320.170.070.41-0.43-0.430.42-0.430.39-0.47-0.02-0.350.11-0.390.03-0.43-0.33-0.33-0.1-0.27-0.32-0.33
0.17-0.3-0.31-0.25-0.94-0.290.280.28-0.270.28-0.280.06-0.020.08-0.560.08-0.56-0.150.220.220.28-0.310.120.22
0.53-0.13-0.490.230.08-0.920.960.95-0.930.95-0.930.99-0.350.080.490.980.520.180.160.16-0.330.610.680.16
-0.010.21-0.060.170.56-0.220.240.2-0.20.2-0.230.480.11-0.560.490.470.890.3-0.22-0.22-0.280.480.31-0.22
0.55-0.1-0.40.290.07-0.890.940.94-0.930.94-0.90.98-0.390.080.980.470.520.260.180.18-0.30.590.670.18
0.010.320.090.370.63-0.210.270.27-0.290.27-0.240.480.03-0.560.520.890.520.250.060.06-0.490.590.420.06
0.050.31-0.120.020.09-0.090.140.1-0.070.1-0.080.27-0.43-0.150.180.30.260.250.080.080.050.190.170.08
-0.030.250.020.03-0.16-0.050.250.26-0.290.25-0.050.15-0.330.220.16-0.220.180.060.081.0-0.440.220.331.0
-0.030.250.020.03-0.16-0.050.250.26-0.290.25-0.050.15-0.330.220.16-0.220.180.060.081.0-0.440.220.331.0
-0.37-0.65-0.24-0.56-0.490.12-0.27-0.290.32-0.290.17-0.26-0.10.28-0.33-0.28-0.3-0.490.05-0.44-0.44-0.61-0.55-0.44
0.130.05-0.010.590.52-0.40.510.53-0.520.52-0.440.6-0.27-0.310.610.480.590.590.190.220.22-0.610.870.22
0.330.04-0.070.470.11-0.530.650.66-0.670.66-0.550.67-0.320.120.680.310.670.420.170.330.33-0.550.870.33
-0.030.250.020.03-0.16-0.050.250.26-0.290.25-0.050.15-0.330.220.16-0.220.180.060.081.01.0-0.440.220.33
Click cells to compare fundamentals

Seelos Therapeutics Account Relationship Matchups

Seelos Therapeutics income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization417K45K343K(2.8M)57K54.2K
Interest Expense29K164K1.6M14K75K71.3K
Selling General Administrative7.6M7.8M15.0M12.3M12.6M8.7M
Other Operating Expenses29.7M18.8M61.7M70.9M42.7M23.6M
Operating Income(29.7M)(18.8M)(61.7M)(70.9M)(40.5M)(38.5M)
Ebit(29.7M)(18.8M)(61.7M)(70.9M)(40.5M)(38.5M)
Research Development22.6M11.0M46.6M58.6M30.1M31.6M
Ebitda(29.3M)(18.7M)(61.3M)(73.8M)(40.4M)(38.4M)
Total Operating Expenses29.7M18.8M61.7M70.9M42.6M22.6M
Net Income(50.4M)(19.2M)(67.5M)(76.1M)(37.9M)(36.0M)
Income Tax Expense(497K)119K1.5M2.6M3.0M3.1M
Income Before Tax(50.9M)(19.1M)(66.0M)(73.5M)(37.9M)(36.0M)
Total Other Income Expense Net(21.1M)(342K)(4.4M)(2.6M)2.6M2.7M
Net Income From Continuing Ops(51.3M)(19.1M)(66.0M)(73.5M)(37.9M)(39.8M)
Non Operating Income Net Other(70K)(21.5M)(178K)(2.6M)(2.3M)(2.2M)
Net Income Applicable To Common Shares(51.3M)(19.1M)(66.0M)(73.5M)(66.2M)(62.9M)
Net Interest Income122K(119K)(1.5M)107K123K129.2K
Interest Income151K45K113K121K198K122.5K

Currently Active Assets on Macroaxis

When determining whether Seelos Therapeutics is a strong investment it is important to analyze Seelos Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Seelos Therapeutics' future performance. For an informed investment choice regarding Seelos Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.
Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Seelos Stock analysis

When running Seelos Therapeutics' price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.73)
Revenue Per Share
0.45
Return On Assets
(1.80)
Return On Equity
(5.84)
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seelos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.